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Piya Das Ghatak 
INHIBITION OF TFEB ACTIVATION PROMOTES COXIELLA BURNETII GROWTH 
Coxiella burnetii is the etiologic agent of Q fever, a zoonotic disease 
characterized by flu-like sickness in acute cases; endocarditis may occur and turn deadly 
if not treated correctly in chronic patients.  
Coxiella, an obligate intracellular bacterium, requires establishment of a 
replicative niche in the host cell. After being phagocytosed by the eukaryotic cell, the 
bacterium resides in a tight-fitting nascent phagosome which matures through the host 
canonical endocytic pathway, acquiring endosomal/lysosomal markers as well as acidic 
pH. Initial acidification of the Coxiella containing vacuole (CCV) is central to the 
bacterium’s pathogenesis because translocation of bacterial effector proteins into the host 
cell by the type 4B secretion system (T4BSS) initiates only after it senses the acidic 
environment. The effector proteins are required for subverting different host cell 
functions in favor of Coxiella growth, CCV maturation and are crucial for bacterial 
virulence.  
Contrary to the belief that since CCV matures through the host endocytic 
pathway, CCV is as acidic as lysosome, we found that CCV is significantly less acidic 
(pH~5.2) than lysosomes (pH~4.8) and inducing further CCV acidification causes 
Coxiella lysis. Furthermore, increasing lysosomal biogenesis in the host cell is 
detrimental for Coxiella growth. So, we hypothesized that Coxiella blocks lysosomal 
biogenesis in host cells to maintain the CCV pH just optimal for its growth. 
Lysosomal biogenesis is regulated by the master transcription factor EB (TFEB). 
Its ability to act as a transcription factor depends on its subcellular localization, which 
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relies on its phosphorylation state. TFEB, when phosphorylated is cytosolic and inactive, 
whereas dephosphorylated TFEB translocates to the nucleus and is active, binding to 
promoter regions of lysosomal genes of the CLEAR network, thus controlling lysosome 
biogenesis. Therefore, we hypothesized that Coxiella blocks TFEB translocation to the 
nucleus, thus inhibiting lysosome biogenesis. 
We determined that Coxiella grows significantly better in TFEB-KO cells than 
they do in parentals. Also, using a torin-induced TFEB translocation model, we observed 
remarkably decreased TFEB activation in the Coxiella infected cells as was evident by 
less TFEB translocation to nucleus. Overall, data obtained from this work suggest that 
Coxiella inhibits lysosome biogenesis by blocking TFEB nuclear translocation. 
    
 
Stacey D. Gilk, PhD, Chair 
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CHAPTER ONE: INTRODUCTION 
History of Q fever: Coxiella burnetii 
A mystifying disease first reported in 1935 among a small number of 
slaughterhouse workers in Queensland, Australia, was initially called abattoir fever, as it 
was consistently prevalent among individuals working with butchering animals at an 
abattoir [1, 2]. The key characteristic feature of the disease was the incapacitating high 
fever accompanied by a headache lasting up to two weeks. These symptoms were often 
presented with pulmonary and influenza-like complications. Since the organism 
responsible was unidentified for a long time, the disease was renamed query fever (Q 
fever) [3]. While investigating the disease, Australian researcher Edward Derrick, 
pathologist in charge at Royal Women’s and Brisbane Hospital, was able to successfully 
infect guinea pigs with blood from infected patients. He sent emulsions of infected guinea 
pig livers to Frank McFarlane Burnet in Victoria, who was able to isolate the pathogen 
and hypothesized it to be of rickettsial origin [4]. His experiments infecting a variety of 
different animal species with the guinea pig liver emulsion revealed pathogenicity and 
virulence information of the organism in different hosts. By employing new staining 
techniques, it was determined that the pathogen was “filter-passing” after all; with the 
ability of surviving in the chorio-allantois of developing eggs without inducing lesions [5, 
6].  
Around the same time, thousands of miles away in the Rocky Mountain 
Laboratory in Hamilton, Montana, in the United States, researchers Herald Cox and 
Gordon Davis were attempting to identify the causative agent of Rocky Mountain Spotted 
Fever from ticks collected at Nine Mile Creek, Montana. This pathogen was named 
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“Nine Mile” and caused febrile illness in guinea pigs infected with blood from diseased 
animals [5]. The first known human transmission case occurred during this time, when 
Rolla Dyer, the future NIH Director, was infected after working with Cox, who became 
infected himself while managing contaminated samples. A series of seminal 
immunological and cross-protection studies demonstrated that guinea pigs which 
recovered from disease caused by Dr. Dyer’s samples were immune to infection with the 
Australian Q fever agent, thus indicating that the Australian Q fever agent and organism 
isolated from ticks in Montana were the same organism [7].  
The pathogen underwent several name changes over the course of about 80 years 
since its first report. Starting from being assumed it was a virus by Derrick, to briefly 
acquiring the names Rickettsia diaporica, followed by Rickettsia burnetii. Eventually the 
name Coxiella burnetii was given to honor both research groups in United States (Herald 
Cox) and Australia (Frank McFarlane Burnet) [8, 9].  
Human and animal disease  
The disease caused by C. burnetii is described as clinically polymorphic, as it can 
manifest into a range of varying forms or types within a single affected species [4]. The 
main reservoirs for C. burnetii are farm animals, such as cattle, sheep, and goats. 
However, studies in recent years indicate that a significant number of domestic and 
marine mammals, as well as reptiles, birds and ticks can also shed the bacteria [10]. 
Regardless of the source, human transmission is primarily achieved by inhalation of 
bacteria-contaminated aerosols spread in the environment. Moreover, some interesting 
reports of infection by tick bites, consumption of milk from contaminated animals, and 
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nosocomial transmission between humans have also been recorded as potential source of 
infection [11-13].  Thus, Q fever is classified as a zoonotic disease.    
In animals, Q fever is mostly asymptomatic, thus making identification of 
infected animals is challenging. Usually, a conclusive test to determine serum antibody 
titers is required to determine the infection. Abortions at the final gestational phase in 
pregnant goats and sheep is the key clinical manifestation of the disease [14]. Up to 90% 
of infected cattle face abortions, which results in bacterial shedding as high as 109/gram 
placenta into the environment [3, 15]. Urine, feces, and milk from these animals also 
contribute to the contaminated aerosol load in the environment.  
Since C. burnetii can resist drying, heat, osmotic pressures, and common 
disinfectants, it is environmentally a very stable pathogen and the contaminated aerosol 
particles can survive and persist for a prolonged period in soil and cause further infection 
in humans. Coxiella has the lowest bacterial infectious dose known; fewer than 10 
bacteria (ID50  = 1) are capable of causing disease [16]. Combined with environmental 
stability and a low infectious dose, C. burnetii fulfills most of the requirements for a 
biowarfare weapon. Before the United States ended its biological warfare program in 
1969, C. burnetii was one of the seven pathogens being pursued as a biological weapon 
[17]. It is currently listed as a category B biological warfare agent by the Centers for 
Disease Control and Prevention (CDC) [18]. 
An earlier 1950 study with 51 human volunteers indicated that most efficient 
route of  human infection was intradermal inoculation, which resulted in 100% 
seroconversion, followed by infected food consumption and intranasal inoculation [19]. 
However, aerosol transmission remains the most common route of infection probably 
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because pasteurization of food decreases the probability of infection by the digestive 
route.  
Although the prevalence of cases varies from one country to another, Q fever has 
been reported across the world, except in New Zealand [15, 20, 21]. However, global Q 
fever incidence and prevalence rates are often poorly characterized due to varying 
reportable symptoms and misdiagnoses.  
Wide state to state variation of Q fever seroprevalence in cattle has been reported 
in the United States, but Coxiella infection has increased in U.S. farm animals during last 
few decades [22]. Despite this rising prevalence of Q fever in cattle, reported cases of 
human infection in the U.S. have been low (Figure 1). According to the most recent 
report from Centers for Disease Control and Prevention (CDC) in 2017, more than one-
third of cases (38%) are reported from states where ranching and raising livestock are 
common. Seasonal trends of Q fever emergence in the country also follows this trend, 
most reported cases of illness begin in spring and early summer months which is the 
birthing season for cattle, sheep and goats [23].  
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Figure 1:   Annual reported incidence (per million people) for Q fever – United 
States for 2017  
In the U. S., Q fever was declared a nationally notifiable disease in 1999. Cases reported 
by state and local health departments are compiled by the CDC to determine national 
trends. Passive surveillance systems for Q fever, compounded with lack of reporting and 
timely diagnosis due to nonspecific presentation are thought to contribute to the 
underrepresented cases. (NN = Not notifiable)   
Figure 1
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In humans, the presentation of Q fever can range from asymptomatic to mildly 
symptomatic seroconversion, which can develop throughout the acute phase of the 
disease, eventually leading to the life-threatening chronic illness. About 60% of human 
infections are asymptomatic [24]. In the majority of infections of otherwise healthy 
individuals, acute disease presents as a self-limiting febrile illness. Symptoms start as flu-
like associated with pneumonia. In chronic disease, which develops in approximately 1-
2% of acutely infected cases, endocarditis is the major disease outcome, especially in 
patients with previous valvulopathy. Host factors, such as age, gender and preexisting 
medical conditions can greatly influence disease symptoms [25].   
In addition to Q fever, Q fever fatigue syndrome (QFS) is a serious clinical 
manifestation of the disease. It is described and well documented in many countries and 
characterized by persistent fatigue condition, which can last between five and ten years in 
10%-15% of the acutely infected population [26]. Though the cause of development of 
this condition is unknown, lack of satisfactory outcome with existent treatment strategies 
is believed to be a critical factor [27]. 
About 370 Q fever outbreaks in different countries have been reported worldwide 
since 1954. Countries such as Australia, USA, Germany, France, The Netherlands, and 
United Kingdom have reported small-scale Q fever outbreak notifications at different 
times. However, the largest Q fever outbreak recorded to date occurred in the 
Netherlands between 2007 and 2010 when a series of community infection cases emerged 
[28]. A high prevalence of spontaneous abortions in goats and sheep was identified as the 
primary source of  infection in humans [29]. The outbreak affected a population with low 
previous Q fever seroprevalence [30]. Based on further studies, over 40,000 people were 
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thought to be infected with C. burnetii. Other than direct exposure to the infected farm 
animals, downwind contaminated aerosols from dairy farms also contributed to the 
spread [31-33]. In December, 2009, the Dutch government decided to systemically cull 
more than 50,000 gestating goats and ewes in an effort to control the disease [34]. This 
veterinary measure along with increased immunization of sheep and goats finally resulted 
in decreased number of reported human cases in 2010.  
Bacteriology 
Coxiella is a small 0.2 to 0.4 μm wide and 0.4 to 1 μm long coccobacillus. It has a 
cell wall similar to that of a Gram-negative bacterium but not stainable with the Gram 
technique. Instead, the Gimenez method is used to stain the bacterium in culture or in 
clinical isolates. Previous studies indicated that the estimated doubling time for Coxiella 
is ~12 h in in vitro conditions, in Vero cells [35]. Once internalized by eukaryotic host 
cells, this obligate intracellular pathogen resides in the phagocytic vacuole and modifies 
the vacuole to form a replicative niche for itself. The bacterium displays antigenic phase 
variation due to the mutational variation in its membrane lipopolysaccharide (LPS) [36]. 
As a result, the bacterium can either have a phase I phenotype identified by the presence 
of complete LPS on cell surface or it can display a phase II phenotype where the 
bacterium expresses a truncated LPS which lack the O-antigen side chains [37]. This 
phase variation is known to be linked to bacterial virulence [38]. Phase I bacteria are 
virulent and capable of replicating in immunocompetent hosts, whereas avirulent phase II 
bacteria are successfully cleared out by host immune response. Phase I to phase II 
transition is primarily associated with the deletion of gene clusters that produce O-antigen 
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of LPS. This shift in phase can occur during repeated bacterial passages in laboratory in 
vitro cultures [39, 40].   
The biphasic developmental cycle of Coxiella involves two forms or variants 
observed in Coxiella based on their size that are clearly distinguishable by electron 
microscopy [41]. The large cell variant (LCV) replicates exponentially and is larger (>0.5 
μm) than the stationary non-replicating small cell variant (SCV) (0.2-0.5 μm). SCVs are 
the extracellular form that are metabolically inactive and highly resistant to stress factors 
such as UV radiation, osmotic, mechanical, chemical, heat and desiccation stresses, 
which make them environmentally very stable so that they can survive in the 
environment for prolonged periods of time [42]. Probably the high number of 
peptidoglycan crosslinks in the membrane confer the stress-resistance property of SCVs 
[43]. LCVs on the other hand, are the metabolically active, intracellular form that is less 
resistant to the environmental stress [41]. The dispersed chromatin in LCV in contrast to 
the condensed chromatin of SCV is also a key difference between the two forms [43].  
The SCVs are observed intracellularly in long term (21 to 28 days) culture of 
Vero cells. The developmental transition and viability of Coxiella were also seen in 
axenic acidified cysteine citrate medium 2 (ACCM2) [44]. This ability of transitioning 
developmental features contributes to the pathogenic efficiency of the bacteria.  
Immunity, treatment, and vaccine 
In its acute form, Q fever is self-limiting and readily resolves without antibiotic 
intervention. The recommended treatment of more life-threatening chronic disease is 
complex, as the only effective therapy requires a daily antibiotic combination of 
doxycycline, a protein synthesis inhibitor along with the alkalizing agent 
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hydroxychloroquine for a minimum of 18 months [45, 46]. This combinatorial treatment 
regimen was shown to be most effective in preventing relapses as well [46]. 
Administration of hydroxychloroquine circumvents resistance against doxycycline, but 
the recent reports of emergence of acquired doxycycline resistance against Coxiella 
emphasizes the need to understand and prevent the pathogenicity [47].  
Discovery of Coxiella as the pathological agent behind Q fever simultaneously 
motivated researchers to develop a human vaccine against the bacterium. A live-
attenuated vaccine was the first to be tested but production was eventually stopped as a 
result of long-term efficacy concerns [48]. Another chloroform-methanol residue extract 
vaccine developed in the US was not even tested in humans as it showed signs of 
reactions in animals [49]. Phase I LPS was known as a key determinant of protective 
immunity in humans, so when various attempts of developing a vaccine were being 
tested, inactivated whole cell phase I strain (Henzerling RSA 334) was a promising 
candidate for this purpose [50]. Further experiments proved that vaccine prepared from 
phase I bacteria was able to elicit better immune response in humans and animals than its 
phase II counterpart [51, 52]. Thus, a whole-cell formalin-inactivated Q fever vaccine (Q-
Vax) was developed which showed a 98% efficacy, a lifelong immunity and was safe 
[50, 53].  However, currently Australia is the only country employing Q-Vax to prevent 
Coxiella outbreak because individuals exposed to Coxiella previously show adverse 
reactions to vaccination. Vaccination with whole-cell bacterium has been shown to cause 
severe local (at the inoculation site) and sometimes systemic reactions [54, 55]. In order 
to prevent such adverse reactions, a screening process has to be completed to test the 
seroprevalence, before clearing the individual to receive the vaccine. This creates a major 
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logistic hurdle in large-scale vaccination strategy. In addition to this, requirement of a 
highly contained BSL-3 laboratory facility for production of this whole - cell vaccine 
makes the vaccine expensive to produce and reproducibility is challenging. A subunit 
vaccine would probably be more efficient in controlling the disease outbreak.  
Coxiella burnetii Type IVB Secretion system  
The majority of intracellular bacterial pathogens possess a specialized secretion 
system which transports proteins across their replicative vacuoles, into the host cytosol. 
These bacterial effector proteins are required to interact with their environment and are 
used to modulate an array of host processes. Dot/Icm proteins of the type 4B secretion 
system (T4BSS) are essential for Coxiella virulence [56]. The Coxiella T4BSS Dot/Icm 
system injects about 130 effector proteins into the cytosol of infected host cells [57]. 
These proteins manipulate different host biochemical, metabolic, inflammatory and 
signaling pathways such as prevention of host cell death, interplay with macrophage 
inflammatory response and interaction with autophagosomes and are necessary for 
bacterial survival, replication, over all virulence; as well as in the development and 
maintenance of the Coxiella-containing vacuole (CCV) [58-60].   
Studies involving Legionella pneumophilia, an evolutionarily related bacterium to 
Coxiella have indicated the presence of more than one secretion systems [59, 61-64]. 
Genomic analysis of Coxiella confirmed that secretion systems type I and II are also 
present in the bacteria, but there is not any study so far confirming their effector 
translocation across CCV membranes [65-67]. Coxiella encodes elements of a Sec-
dependent secretion pathway, as well as a complete T4BSS, which translocate effector 
proteins across vacuolar and bacterial membranes and shape its replicative niche [67, 68].  
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Intracellular lifestyle of Coxiella burnetii 
Although multiple intracellular resident phagocytic and non-phagocytic cells 
including neutrophils, fibroblasts, epithelial cells, endothelial cells, and 
interstitial/alveolar macrophages are present in the lung environment, alveolar 
macrophages remain the primary and preferential target of Coxiella infection[69, 70]. 
Coxiella enters the cell by a passive actin-dependent phagocytosis. Once internalized, 
instead of using mechanisms to escape endocytic pathways, Coxiella remains encased in 
its phagosome and eventually modifies it to develop a lysosome-like replicative niche 
[71]. This compartment, called the Coxiella containing vacuole (CCV) matures along the 
endocytic pathway acquiring various markers of the endolysosomal system (Figure 2) 
[72-75]. Interestingly, this initial part of the endocytic pathway is host canonical and does 
not require bacterial modulation, which is consistent with the observation that Coxiella 
Dot/Icm (defect in organelle trafficking/intracellular multiplication) system is not 
functional at this early stage of infection [60, 71, 76]. It is speculated that Coxiella has 
evolved this fine-tuned mechanism to regulate the Dot/Icm system effector secretion such 
























Figure 2: Intracellular lifestyle of Coxiella 
Coxiella is phagocytosed primarily by macrophages, but non-phagocytic cells such as fibroblasts and epithelial cells can 
also take up Coxiella. Uptake of Coxiella is followed by maturation of the nascent tight-fitting phagocytic vacuole via its 
fusion with various host endocytic components. Bacteria grow in the expanding CCV over time and T4BSS effector 




During its maturation, the CCV progresses through the host endocytic pathway 
traffic and fuses with host late endosome and lysosomal vesicles, thus forming an 
expanded and large phagolysosomal compartment. Moreover, as a result of this, the CCV 
acquires different endosomal markers indicative of their respective maturation stages, 
along with progressive acidification of the vacuole [75].  
Whereas intracellular pathogens such as Toxoplasma gondii, Chlamydia 
trachomatis and Legionella avoid the bactericidal endosomal maturation altogether, 
Coxiella survives in the phagolysosomal environment derived from fusion of CCV with 
different endocytic vesicles [75, 77]. Earlier biochemical studies have also proved that at 
a neutral pH of 7, Coxiella undergoes minimal metabolic activity, but acidification of the 
media stimulated glucose metabolism [78, 79]. Thus, acidification of nascent phagosome 
is required to activate bacterial metabolism and secretion system [58]. CCV acidification 
is required for successful effector delivery by Coxiella [79]. As early as 8 hours post 
infection, once the bacterium is in the acidified environment of a late endocytic organelle, 
the T4BSS system is activated and effector proteins start to translocate across the CCV 
membrane into the host cytosol [61, 80, 81].  
However, Coxiella is unique in its active, T4BSS-dependent regulation of the 
CCV acidification process, as demonstrated by recent findings from our lab that not only 
is CCV less acidic than a mature lysosome, but Coxiella is so sensitive to more acidic 
environment, that further lowering of the pH of the CCV causes bacterial lysis [58, 82]. 
Furthermore, using a T4BSS mutant deficient in Dot/Icm function (ΔdotA), we were able 
to prove that pH of mature endosomes is manipulated by Coxiella and the endosomes 
from ΔdotA Coxiella infected are significantly more acidic than the endosomes from WT 
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Coxiella infected cells [58]. This was a surprising and groundbreaking finding because 
this observation suggested that there were reduced number of proteolytically active 
lysosomes available to fuse with CCV as a result of less acidic terminal endocytic 
vesicles present in infected cells than in the uninfected ones, as a mechanism to modulate 
CCV pH. Indeed, cathepsin B Magic Red assay to identify proteolytically active 
lysosomes revealed that WT Coxiella–infected cells had significantly reduced cathepsin 
B activity than the mock-infected controls [58]. This observation changed the long-
standing notion that even though CCV is a lysosome-derived compartment, and the initial 
CCV acidity is necessary to drive Coxiella metabolism, it is not as acidic as a lysosome. 
We confirmed that Coxiella regulates CCV and endosomal pH in infected host cells and 
actively regulates CCV pH at a stable range of  ~5.2 during a 6 day infection [58].  
Starting from the initial observation that increasing acidity by decreasing CCV pH 
is detrimental for Coxiella, we established that in contrast to previous belief, lysosomes 
and terminal endocytic vesicles are less acidic in the infected cells, which results in 
formation of less acidic CCV from heterotypic fusion, and this process is regulated by 
Coxiella actively. Our findings were further reinforced by the observation that increasing 
lysosomal content of a cell by enhancing lysosomal biogenesis significantly inhibited 
Coxiella growth [58]. However, how Coxiella subverts host lysosomes is not fully 
understood. 
Lysosomal biogenesis and Transcription factor EB (TFEB) in relation to Coxiella  
Lysosomal genes primarily belong to a network called Coordinated Lysosomal 
Expression And Regulation (CLEAR) [83]. Promoter region analysis of 96 known 
lysosomal genes indicated that 68 of them have a palindromic 10 bp consensus region 
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[84]. This motif was located within 200 bp of transcription start sites (TSS) in humans 
suggesting their role in transcriptional activation of these genes and is known as the 
CLEAR motif. Transcription factor EB (TFEB) directly binds to this promoter site and 
thus, is known as master regulator of the CLEAR network. One or more in tandem 
CLEAR motif(s) have been identified in the promoter region of many lysosomal genes, 
including those that encode for lysosomal membrane proteins, hydrolases, accessory 
proteins, and biogenesis proteins. As depicted in figure 3,the majority of the genes in the 
CLEAR network are involved in lysosomal biogenesis and function (genes encoding 
subunits of vacuolar proton pump, responsible for creating and maintaining lysosomal 
acidic environment, lysosomal membrane proteins and autophagy proteins) as well as in 
synthesis of lysosomal hydrolase, transporter and accessory proteins [85]. Table #1 lists 
the genes that are TFEB direct targets with known lysosomal functions [85]. TFEB 
overexpression results in upregulation of 291 genes, most of which are related to 
lysosomal biogenesis and function further emphasizing the role of TFEB in lysosome 
homeostasis in the cell [86]. TFEB is a therapeutic target for lysosomal storage disorders, 
neurodegenerative diseases, and different types of cancer [87-90]. Interestingly, a recent 
study with two intracellular bacteria, Mycobacterium tuberculosis and Burkholderia 
cenocepacia have shown that TFEB induced lysosome biogenesis boosted the ability of 
macrophages to eliminate the pathogen, methicillin-resistant Staphylococcus aureus in a 




Figure 3: Lysosomal functional categories controlled by CLEAR network 
Characterization of CLEAR network revealed gene categories associated with lysosomal 















Category Gene name 
Lysosomal hydrolases and
accessory proteins
ASAH1, CTSA, CTSB, CTSD, CTSF, GAA,
GALNS, GBA, GLA, GLB1, GNS,
GUSB, HEXA, HEXB, IFI30, NAGLU,
NEU1, PLBD2, PPT1, PSAP, SCPEP1,
SGSH, TPP1
Lysosomal membrane C1orf85, CD63, CLCN7, CLN3, CTNS,
MCOLN1, SLC36A1, LAMP1,
TMEM55B







NAGPA, GNPTG, IGF2R, M6PR,
BLOC1S1, BLOC1S3, HPS1, HPS3,
HPS5, SUMF1
Autophagy BECN1, GABARAP, HIF1A, NRBF2,
PRKAG2, RAB7A, RRAGC, SQSTM1, STK4, 




Table 1: TFEB direct target genes with known roles in lysosome function  











TFEB also regulates another important eukaryotic cellular clearance process, 
autophagy, by which damaged organelles, invading pathogens and defective cellular 
components including misfolded proteins are cleaned out of cells. The Coxiella-
containing nascent tight-fitting phagosome interacts with autophagosomes and displays 
LC3 protein, a marker of autophagic vacuoles at a time point as early as 18 h post-
infection [92]. Early stage interference of autophagy using inhibitors blocked CCV 
formation[92]. These findings showed that CCV formation is closely related with 
autophagy and Coxiella utilizes this host machinery to thrive. Autophagy related genes 
are transcriptionally regulated by TFEB and as a result TFEB activation results in a 
remarkable increase in autophagic flux [85, 93]. However, recent work from our lab has 
shown that Coxiella reduces lysosomes in infected cells in a manner independent of 
autophagy [94].  
This observation further supports our hypothesis that Coxiella blocks CCV 
acidification by impeding lysosomal biogenesis, which is mediated by inhibition of TFEB 
activation. TFEB mediated promoter binding and elevated gene expression is dependent 
on its cytosol-to-nucleus translocation. TFEB activation and the resulting translocation 
are largely dependent on the phosphorylation status of TFEB. Phosphorylated TFEB is 
sequestered into the cytosol, thus the transcriptional induction of its target genes is 
inhibited. Conversely, when TFEB is dephosphorylated, it rapidly translocates to the 
nucleus, where it binds to the promoter regions of its target genes, thus initiating their 
transcription. There are several kinase regulators such as GSK3B, AKT, mechanistic 
target of rapamycin (mTOR) and ERK2, as well as phosphatases, such as calcineurin, that 
modulate TFEB phosphorylation by acting on the key TFEB amino acid residues. mTOR 
19 
 
is one of the most important kinases regulating TFEB phosphorylation, since both ERK 
and GSK3 kinases are not able to phosphorylate TFEB in the absence of mTOR activity 
[95]. Thus, mTOR mediated TFEB phosphorylation is a key event that determines 











Figure 4: Schematic diagram describing mechanisms by which TFEB is activated 
and lysosome biogenesis is initiated 
A substantial fraction of endogenous cytosolic TFEB is phosphorylated under basal 
conditions, thus inactive. Dephosphorylated TFEB translocates to nucleus, where it 
actively functions as the master regulator of the CLEAR network by inducing the 
transcription of lysosomal genes after binding to their promoter sequence. Retention of 
TFEB in the cytosol is determined by its mTOR-mediated phosphorylation. Phospho-
TFEB complexes with 14-3-3, a chaperone protein, masks nuclear localization signal and 
thereby barring TFEB nuclear entry. Dephosphorylation of TFEB by calcineurin, a 
protein phosphatase, results in dissociation of TFEB from 14-3-3, and TFEB readily 















Given our finding that Coxiella actively regulates the CCV pH by manipulating 
the host cell in a way that results in reduced number of mature endosome/lysosome 
available for fusion with CCV and the role of TFEB in lysosome biogenesis, we 
rationalized that increased lysosome biogenesis by TFEB overexpression might have a 
detrimental effect in Coxiella viability. Indeed, published reports from our lab showed 
that CCVs in TFEB overexpressing Hela cells were significantly smaller in size and they 
never expanded over a 6 days experimental time period. Moreover, Coxiella growth was 
found to be significantly reduced in these TFEB overexpressing cells. pH measurement 
assay revealed that the CCVs in TFEB overexpressing cells were more acidic than the 
ones in parental cells. Taken together, these findings suggested that increased lysosome 
biogenesis as a result of TFEB overexpression resulted in increased acidification of CCV, 





CCVs, even though they are derived from host endocytic pathways, are distinctly 
different from the mature lysosomes of the host cell. In two different seminal studies 
from our lab, we showed that acidification of CCV by cholesterol accumulation in CCV 
membrane led to bacterial lysis. Further, we determined that the CCV and mature 
endocytic vesicles of Coxiella-infected cells are remarkably less acidic than the 
lysosomes of uninfected cells and biogenesis of host lysosomes by TFEB overexpression 
is detrimental for Coxiella growth [58, 82]. Based on these observations our next logical 
step was to test whether decreased lysosome biogenesis by complete TFEB knockout had 
any growth effect on Coxiella, followed by understanding the mechanism more 
comprehensively by which Coxiella manipulates the host endocytic pathway in its favor. 
Understanding this mechanism could be useful in discovering more efficient therapeutics 
for Q fever treatment in long term. With this aim in mind, we wanted to examine whether 
the lysosome biogenesis pathway is altered in Coxiella infected cells and how the 
bacterium is modulating it.  
As described before, TFEB is the master regulator of lysosome biogenesis.  
Regulation of TFEB involves a dynamic process related to its subcellular localization. 
The shuttling of TFEB between cytoplasm and the nucleus is regulated by mTOR. Based 
on our findings, we hypothesized that Coxiella blocks the activation of TFEB to prevent 
lysosomal maturation, so that it can maintain a pH just ideal for its growth.  
In order to test this hypothesis and elucidate the mechanism, we took the 
following approaches. Firstly, we tested whether Coxiella growth is promoted in TFEB 
KO cells which have decreased expression of lysosomes. Secondly, we wanted to see 
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whether Coxiella infection inhibits TFEB nuclear translocation in the infected cells 
compared to the uninfected ones. Conducting these studies would allow us to understand 







CHAPTER TWO: MATERIALS AND METHODS 
Bacterial strains and mammalian cells 
mCherry-expressing C. burnetii NMII was purified from Vero cells (African 
green monkey kidney epithelial cells [ATCC CCL-81; American Type Culture 
Collection, Manassas, VA]) and stored as previously described [82]. The multiplicity of 
infection (MOI) of the bacterial stock was optimized for each cell type and culture vessel 
used to ~1 internalized bacterium per cell at 37°C and 5% CO2. Human cervical 
epithelial cells (HeLa, ATCC CCL-2) were maintained in RPMI (Roswell Park Memorial 
Institute) 1640 medium (Corning, New York, NY, USA) containing 10% fetal bovine 
serum (FBS; Atlanta Biologicals, Norcross, GA, USA) and 2 mM L-alanyl-L-glutamine 
(glutagro; Cat. 25-015-CI, Corning, New York, NY) at 37°C and 5% CO2. The wild type 
(parental) and TFEB knockout HeLa cells (generously provided by Richard J. Youle) 
were maintained in DMEM (Dulbecco’s Modified Eagle Medium; Corning) containing 
10% FBS at 37°C and 5% CO2 [101]. 
Lysosome-associated membrane protein 1 (LAMP1) immunostaining 
Wild type (parental) and TFEB KO HeLa cells were seeded on coverslips in 24-
well plates (5 X 104 cells per well, three wells for each cell type). The next day cells were 
fixed in 2.5% paraformaldehyde (Cat. 15710, Electron Microscopy Sciences; Hatfield, 
PA, USA) for 15 min and blocked/permeabilized for 20 min in 1% bovine serum albumin 
(BSA) and 0.1% saponin in PBS. Cells were then incubated with rabbit anti-LAMP1 
(1:1000; Cat. ab24170 Abcam, Cambridge, MA) for 1h followed by Alexa fluor 568 
secondary antibody (1:1000; Life Technologies) for 1 h. Following washing with PBS, 
coverslips were mounted using ProLong Gold with 4’, 6’-diamidino-2 phenylindole 
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(DAPI) (Life Technologies) and visualized on the fluorescent microscope using oil 
immersion objective as described previously [58]. Images were captured and processed 
identically and the fluorescent intensity of LAMP1 was measured (ImageJ). At least 30 
cells were measured per condition for each of three independent experiments. 
Microscopy 
Immunofluorescent images were obtained using a Nikon TiE fluorescent 
microscope (60 X oil immersion objective) and at least 30 CCVs and cells were 
visualized for each condition during three biological replicate experiments. All images 
were analyzed using the FIJI ImageJ software. 
TFEB immunoblotting 
 
Parental and TFEB KO HeLa cells were seeded in a 24-well plates (2.5X104 
cells/well). The next day cells were lysed with 2% sodium dodecyl sulphate (SDS) in tris-
buffered saline (TBS), and analyzed by immunoblotting to confirm TFEB KO. Protein 
lysates were resolved in 10% SDS-PAGE and transferred to PVDF membrane (Cat. 
IPFL00010, Millipore, Burlington, MA). The membrane was then probed using rabbit 
anti-TFEB antibody (1:1000; Cat. 37785, Cell Signaling Technologies, Danvers, MA) in 
1% BSA in PBS, where GAPDH was used as loading control. After washing, the blot 
was incubated with horseradish peroxidase-conjugated anti-rabbit (1:1000; Cat. 31460, 
Thermo Fisher) or anti-mouse (1:1000; Cat. 31430, Thermo Fisher) secondary antibody 
in 4% non-fat milk in TBS-T (TBS containing 0.05% tween-20), and developed using 
enhanced chemiluminsence (ECL) reagent (SuperSignal West Pico PLUS; Cat. 34580, 





Subcellular fractionation  
 
HeLa cells harvested 3 days post-infection with WT C. burnetii were subjected to 
a detergent based cellular fractionation using cytoplasm and nucleus isolation buffers 
provided with the cell fractionation kit (Cat# 9038, Cell Signaling technology, Danvers, 
MA). Briefly, cells were lysed to collect whole cell lysate, cytoplasmic fraction and 
nuclear fraction. After the fractions were collected, they were probed for detection of 
TFEB by resolving the samples on SDS gel in an immunoblotting assay. Purity of the 
fractions were also checked by probing them with cytosolic or nuclear markers, such as 
GAPDH and histone, respectively.  
Colony forming unit (CFU) assay 
 
Parental and TFEBKO HeLa cells were plated in 6-well plate (2 X 105 cells per 
well) and allowed to adhere overnight. The cells were infected with wild type C. burnetii 
in 0.5 mL DMEM for 2 h, washed extensively with PBS, and 2 mL of fresh 10% DMEM 
was added to each well. Infected cells were replated into a 24-well plate (2.5 X 104 
cells/well for day 3, and 5 X 103 cells/well for day 6). To determine day 0, a fraction of 
infected cells was collected and lysed in sterile water for 5 min. The released bacteria 
were diluted 1:5 in ACCM-D and plated in 5-fold serial dilutions onto 0.25% ACCM-D 
agarose plates [58]. For the subsequent time points, the cells were lysed in sterile water 
for 5 min and the released bacteria were diluted 1:5 in ACCM-D and spotted in 10-fold 
serial dilutions onto 0.25% ACCM-D agarose plates. The plates were incubated for 7 to 9 
days at 37°C in 2.5% O2 and 5% CO2, and the number of colonies counted to measure 
bacterial viability. Number of day 3 and day 6 colonies were normalized over that of day 
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0 CFU. Each of the three experiments was performed in biological duplicate, and the 
bacteria were spotted in triplicate. 
Quantification of CCV size 
 
Parental and TFEBKO HeLa cells were plated in a six well plate (2 X 105 
cells/well) and allowed to adhere overnight. Cells were infected with wild type mCherry-
WT C. burnetii for 2 h, washed extensively with PBS, and scraped into 2 mL of 10% 
DMEM. Infected cells were replated onto coverslips in a 24 well plate (2.5 X 104 
cells/well for day 2, and 5 X 103 cells/well for day 6). At the indicated time points, cells 
were fixed with 2.5% PFA for 15 min, washed in PBS, and blocked/permeabilized in 1% 
BSA and 0.1% saponin in PBS for 20 min. Coverslips were stained with mouse anti-
CD63 (1:1000; Cat. 556019; BD Biosciences, San Jose, CA) for 2 h, followed by Alexa 
Fluor 647 secondary antibody (1:1000; Invitrogen) for 1 h [58]. Following washing with 
PBS, coverslips were mounted with ProLong Gold with DAPI and visualized on a Nikon 
TiE microscope (60X oil immersion objective). Images were captured and processed 
identically, and the CCV area was measured using ImageJ software. At least 30 CCVs 
were measured per condition for each of three independent experiments. 
Statistical analysis 
Statistical analyses were performed using the Prism software using unpaired 
student t-test, or ordinary one-way ANOVA (with Tukey’s correction) as appropriate in 
GraphPad (GraphPad Software, Inc., La Jolla, CA). 
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CHAPTER THREE: RESULTS 
Validation of decreased lysosome biogenesis in TFEB KO cells 
 Recent published work from our lab showed that our TFEB overexpressing 
TFEB-GFP cells have increased proteolytically active lysosomes as was evident from 
cathepsin B activity compared to the parental cells [58]. This observation agrees with a 
previously reported study where TFEB overexpression resulted in increased lysosomal 
biogenesis as indicated by LAMP1 immunostaining in a stably transfected TFEB 
overexpressing HeLa cell system [84]. Infection of these cells with Coxiella revealed that 
increased lysosomes in host cells is detrimental for its growth [58]. Part of the long-term 
goal of the current study is to determine if Coxiella can block TFEB activation leading to 
inhibition of lysosomal biogenesis. To this end, examining the effect of complete loss of 
endogenous TFEB expression on Coxiella growth would provide us some insight on the 
bacterial viability in decreased lysosome condition.  An approach to test that would be to 
employ TFEB KO HeLa cells generated by CRISPR/Cas9-mediated gene KO system and 
infect them with WT Coxiella [101]. Before conducting Coxiella viability experiments 
with TFEB KO cells, we wanted to validate these stable cells by testing their lysosomal 
content. We used LAMP-1 immunostaining to quantify lysosomes and compare the 
expression of LAMP-1 intensity. Parental HeLa cells were used as control. After 
identically acquiring the images of the cells, the LAMP-1 intensity was measured and 
quantified in ImageJ software. As expected, we observed that there was significantly less 
LAMP-1 expression in the TFEB KO cells (Figure 5 A and B). 
We also validated the TFEB KO cells by performing immunoblotting for TFEB 
expression. As expected, lysate from TFEB KO cells showed no TFEB expression, 
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confirming complete TFEB has been disrupted in these cells (Figure 5 C).  These two 
experiments proved that our TFEB KO cell system to be tested further with Coxiella 
infection model indeed has decreased lysosomes as a result of TFEB knockout.  
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Figure 5: TFEB knockout results in decreased lysosomal biogenesis in HeLa cells  
A. Representative images of LAMP1(lysosome marker) immunofluorescent staining in 
parental and TFEB KO cells. B. Quantitation of LAMP1 intensity in the parental and 
TFEB KO cells (each circle represents an individual cell) revealed decreased lysosomal 
biogenesis in the TFEB KO cells compared to the parental cells. Data shown as mean ± 
SEM of at least 30 cells per condition in each of three independent experiments as 
analyzed by student’s t-test. C. Immunoblotting of whole cell lysate confirmed that there 























TFEB knockout results in bigger CCV size  
Previous study from our lab using WT Coxiella-infected TFEB overexpressing 
and parental cells showed that TFEB-induced lysosome biogenesis inhibited Coxiella 
growth [58]. To test how ablation of TFEB expression affects Coxiella growth, parental 
and TFEB KO cells were infected with mCherry-expressing Coxiella. Immunostaining 
with CD63, a CCV marker was performed. Cells were counter-stained with DAPI. 
Immunofluorescent images were analyzed by microscopy 3 days and 6 days post-
infection (dpi) and the images were analyzed on ImageJ software. CCV size was 
significantly bigger in TFEB KO cells compared to the parental (Figure 6).  Bigger CCV 






Figure 6: TFEB knockout results in bigger CCV size 
A. Representative images of immunofluorescence staining of WT mCherry expressing C. 
burnetii-infected parental and TFEB KO HeLa cells at 3 days and 6 days post-infection 
(dpi). Fixed cells were stained for CD63, a CCV marker. Arrows point to individual 
CCVs. Qualitatively, TFEB KO cells contained bigger CCVs compared to parental cells 
at both time points. B. Quantitation of CCV size in parental and TFEB KO cells revealed 
significantly bigger CCVs in TFEB KO cells compared to parental cells at both time 
points. Each circle represents an individual CCV. Data shown as mean ± SEM of at least 
35 CCVs per condition in each of three independent experiments as analyzed by unpaired 



































TFEB knockout promotes Coxiella growth  
 Given that the CCV size is considerably bigger in TFEB KO cells infected by WT 
Coxiella, we sought to test whether this observation reflects in Coxiella growth as well. 
Quantitative agarose-based colony forming unit (CFU) assay showed that compared to 
parental cells, Coxiella growth was significantly higher at both 3 and 6 dpi timepoints in 
the TFEB KO cells (Figure 7). Data depicted in figures 6 and 7 suggested that decreased 
lysosomal biogenesis in TFEB KO HeLa cells promote Coxiella intracellular growth 
accompanied by larger CCV formation. These data are also in agreement with previous 
findings from our lab where we had observed TFEB-induced lysosome biogenesis 




Figure 7: TFEB knockout promotes bacterial growth 
A and B. Quantitative CFU assay revealed a significant increase in bacterial growth in 
TFEB KO cells compared to parental cells. C. burnetii growth is plotted as a fold change 
of CFU over day 0 well at each time point. Data shown as mean ± SEM from six 

































Coxiella infection inhibits torin-induced TFEB nuclear translocation in transiently 
transfected cells (induced TFEB expression)  
Our findings that Coxiella growth is enhanced in TFEB KO cells, suggested that 
Coxiella manipulates the host cells in a way that lysosome biogenesis is inhibited upon 
infection. TFEB is the master regulator of lysosomal genes and its functional activation is 
regulated by phosphorylation and subsequent subcellular localization. TFEB 
phosphorylation is mediated by mTOR. Thus, we hypothesized that in WT Coxiella 
infected cells TFEB activation is inhibited.  
To test this hypothesis, we transfected HeLa cells with a TFEB-GFP plasmid and 
infected these cells with WT Coxiella. At three days post infection, cells were treated 
with torin for two hours in a dose–dependent manner (data not shown).  Torin is a kinase 
inhibitor drug and torin-mediated nuclear translocation of TFEB is a well-studied model 
in mTOR research area. There are multiple studies exploiting the mTOR inhibitory 
property of torin [101-103]. Essentially, torin inhibits mTOR by targeting its catalytic 
activity, thus causing a significant increase in nuclear translocation of TFEB and 
activating it. Microscopically, the reduction in diffused cytoplasmic pool of TFEB signal 
can be observed after torin treatment [104]. Torin-treated uninfected cells showing 
massive TFEB nuclear localization served as a positive control in this experiment. 
Controls also included i) DMSO (vehicle) treated cells, ii) untreated and uninfected but 
transfected cells, and finally iii) non-transfected and untreated cells (negative control). 
Cells colocalized with TFEB-GFP (transfected) and DAPI stain were deemed as positive 
for TFEB nuclear translocation. % TFEB translocated to nucleus was quantified by 
measuring the intensity of green TFEB signal in cytoplasm and nucleus using ImageJ 
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software. Images were analyzed using ImageJ software. WT Coxiella infected cells have 















Figure 8: Coxiella infection inhibits torin-induced TFEB nuclear translocation 
(activation) in transiently transfected HeLa cells (induced TFEB expression)  
HeLa cells were transfected with TFEB-GFP plasmid and 24 hours post transfection, WT 
mCherry expressing Coxiella-infected HeLa cells were treated with DMSO or torin 3 
days post-infection. Cells were then fixed and stained with DAPI before imaging. As 
seen from the quantitation, there was decreased torin-induced TFEB translocation to 
nucleus in the infected cells compared to the uninfected cells. In other words, there was 
less activated TFEB in the infected cells than the uninfected cells. At least 30 
cells/condition were imaged. Data shown as mean ± SEM from four independent 





Coxiella infection inhibits torin-induced TFEB nuclear translocation in cells 
(endogenous expression) 
In order to determine whether the inhibited nuclear translocation of TFEB in 
transiently induced HeLa cells upon WT Coxiella infection is also observed in cells 
endogenously, we tested the presence of TFEB protein in cytosolic and nuclear fractions 
of the uninfected and WT Coxiella-infected cells through immunoblotting. We used an 
optimum dose of 50 nM torin as we did for the previous experiment. We used torin and 
DMSO controls as described previously. In this cell fractionation-based assay, 
immunoblotting of nuclear and cytosolic fractions for TFEB was performed. We used 
GAPDH and histone as cytosolic and nuclear markers respectively, to test the purity of 
the fractions. As indicated in figure 9, there was a prominent decrease in the TFEB 
translocation in the nuclear fraction of infected cells. This experiment further confirmed 
that Coxiella caused an inhibition of host cell TFEB translocation to the nucleus, which 
may result in decreased transcription of CLEAR genes leading to less lysosomal 












Figure 9: Coxiella infection inhibits torin-induced TFEB nuclear translocation 
(activation) in HeLa cells (endogenous expression)  
Immunoblot for total endogenous TFEB revealed that WT Coxiella infection inhibits 
nuclear TFEB translocation in HeLa cells treated with torin 3 days post infection. 
Compared to the uninfected cells, the infected cells showed less TFEB translocated to 











CHAPTER FOUR: DISCUSSION 
 Coxiella is a pathogenic intracellular bacterium which was long believed to be 
unique because it was thought to be residing and replicating in the degrative acidic 
environment of lysosomes. Unlike other intracellular pathogens, Coxiella depends on the 
host cell to be delivered to a lysosomal environment. Once the bacterium senses the 
acidic environment of an endocytic vacuole, its Dot/Icm secretion system and metabolism 
are activated, followed by initiation of effector secretion. The effector proteins play 
important roles in Coxiella pathogenesis and replication. Five effector proteins, referred 
to as Coxiella vacuolar proteins (Cvp A to E), for example, are localized at CCV and 
mutations in cvp genes affects CCV biogenesis and Coxiella replication [105]. Unlike 
other pathogens that are internalized in the cell by the host endocytic pathway and reside 
in multiple, small tight-fitting vacuoles, CCVs are highly fusogenic, and mature CCVs 
are often large enough to occupy the entire cell cytosol, pushing the cell organelles to a 
side. Homotypic fusion of CCVs are mediated by the host component syntaxin-17 and the 
bacterial component CvpB/Cig2. Syntaxin - 17 is an autophagy -related SNARE protein 
and this host-bacterial interaction is an example of how an effector protein manipulates 
and uses host system for its own benefit [106, 107]. Components of the host autophagic 
pathways are also involved in membrane repair caused by damage in CCV [108]. 
Moreover, induction of autophagy has shown to be beneficial for generation and 
maturation of CCV [109]. Thus, autophagy pathway is closely modulated by and linked 
to CCV development.  
In a recent study from our lab, we were able to prove that even though CCV is a 
niche derived from the host endocytic pathway, and its maturation is closely linked with 
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the host endolysosomal system, it is not as acidic as a mature endosome. In fact, while 
the initial acidification of CCV is required by the bacterium to successfully reside and 
replicate in the host cell, further acidification is detrimental for its growth [60]. The 
observation that inducing CCV acidification to pH ~4.8 led to bacterial death led us to 
investigate the endosomal maturation in Coxiella infected cells. We found that CCV pH 
(~5.2) is significantly less acidic than the lysosomes of uninfected host cells (~4.8). Close 
examination and comparison between pH of uninfected and Coxiella infected lysosomes 
suggested that the pH of endosome in uninfected cells was 4.9, compared to the pH ~5.8 
in infected cells. Not only this, increased lysosomal biogenesis led to decreased bacterial 
growth accompanied by smaller CCVs [58]. The current study reported in the scope of 
the thesis work is based on this seminal finding. We wanted to understand the mechanism 
by which Coxiella maintains a pH just right for its sustenance by reducing the availability 
of mature lysosomes in the infected cells.  
   Autophagy and lysosomal biogenesis are two crucial parts of the eukaryotic 
endolysosomal system. However, we found out that the reduction of lysosomes in 
infected cells is independent of autophagy and blocking autophagy did not affect 
lysosomal content [58]. So, lysosome biogenesis via regulation of TFEB was an 
important component that we wanted to investigate further. Experiments involving 
overexpression of TFEB and resulting increased lysosome biogenesis caused remarkably 
decreased viability of Coxiella [58], whereas complete TFEB ablation (Figures 5 and 6) 
or partial siRNA mediated TFEB silencing (unpublished data)resulted in increased 
bacterial growth. We observed similar trends in the CCV size - smaller CCVs where 
lysosome biogenesis was increased, larger CCVs where lysosome biogenesis was 
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compromised. These observations proved our hypothesis that Coxiella manipulates 
lysosome biogenesis possibly by modulating the TFEB mediated regulation of the 
CLEAR network.  
Under basal conditions, a substantial fraction of total TFEB is phosphorylated and 
cytosolic, and thus inactive. Nuclear TFEB, on the other hand, is dephosphorylated and 
actively functions as the master regulator of the CLEAR network by inducing the 
transcription of lysosomal genes after binding to their promoter sequence. Retention of 
TFEB in the cytosol is determined by its mTOR-mediated phosphorylation status. 
Phospho-TFEB complexes with a chaperone protein 14-3-3, thus masking a nuclear 
localization signal (NLS), thereby precluding TFEB nuclear entry. Dephosphorylation of 
TFEB by calcineurin results in dissociation of TFEB from 14-3-3, which readily 
promotes its translocation to the nucleus, resulting in activation of the CLEAR network 
[110].  
Several studies have shown that phosphorylation at specific serine residues (S211, 
S142 and S138) are specifically crucial for TFEB subcellular localization, and activation 
[93, 111, 112].  From our preliminary data using an antibody directed to the detection of 
total endogenous TFEB protein, we observed that there was decreased TFEB in the 
nuclear fraction of WT Coxiella infected HeLa cells 3 days post-infection, compared to 
their uninfected counterpart (Figures 8 and 9). Torin, which inhibits mTOR and causes a 
massive TFEB nuclear translocation was used a positive control, along with DMSO 
negative control. Cells were harvested 2 hours post-torin treatment. This interesting 
observation led us to conclude that even in a torin-induced condition, where TFEB is 
expected to be dephosphorylated and massively translocate to nucleus, Coxiella was able 
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to block the TFEB translocation to nucleus, thus blocking lysosome biogenesis (Figure 
10). Future experiments will be focused on determining the phosphorylated and 
dephosphorylated TFEB ratio in the nucleus and cytoplasm of Coxiella infected cells and 
identifying the serine residues differentially phosphorylated in these cells. These data will 
provide further insight on the mechanism of fine-tuned regulation of lysosome biogenesis 







Figure 10: Summary of results 
Coxiella is sensitive to acidic lysosomal environment and actively regulates CCV pH to maintain its growth and pathogenesis. 
While previous work from our lab has shown that Coxiella does this by inhibiting endosomal maturation, thus decreasing 
available acidic endosome/lysosome that can fuse with the CCV, this present work indicates that Coxiella might also 
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For a more detailed and comprehensive understanding of this mechanism, 
phospho-specific antibodies should be used, which are able to recognize the 
phosphorylation state of specific amino acid residues. Phospho-specific antibodies for 
TFEB S142, TFEB S211 and TFEB S138 will be used in immunoblotting experiments. 
Understanding the mechanism behind TFEB inhibition upon Coxiella infection will be 
crucial in ways beyond Coxiella pathogenesis, such as in neurodegenerative disorders and 
cancer, where TFEB is induced or inhibited, respectively.  
Previous studies have proved that translocation of effector proteins by Coxiella 
into the host cytosol are essential for a successful infection. About 354 candidate Coxiella 
effectors have been identified, 130 of which are secreted in a Dot/Icm dependent manner 
[113]. Previous data from our lab indicated that Coxiella effector proteins that manipulate 
host endosomal maturation are T4BSS dependent. So as part of the overall research goal, 
in the second part, we want to focus on T4BSS and work on identifying effector proteins 
targeting TFEB [58].  So, we will identify the protein using an unbiased screening 
approach. We expect to be able to identify effector protein belonging to the T4BSS, along 
with potential proteins belonging to other secretory pathway or system. Collectively, 
observations and findings from this study accompanied by the future scope of work 
described here will highlight the TFEB mediated lysosome biogenesis modulation in 
Coxiella-infected cells, which can be potentially useful beyond understanding Coxiella 
pathogenesis, such as in neurodegenerative disorders and cancer, where TFEB is induced 
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